Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Recruiting · NCT03539822 · Registry updated 2026-01-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal adenocarcinoma, gastric cancer, gastric neoplasm, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-21 | NCT03539822 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anwaar Saeed | 3 |
| AstraZeneca | 806 |
| Exelixis | 77 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Kansas Cancer Center | Westwood | United States | 36 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |